Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model | Zendy

C. H. Chilton | Zendy; Jane Freeman | Zendy; G. S. Crowther | Zendy; S. L. Todhunter | Zendy; Scott Nicholson | Zendy; M. H. Wilcox | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model

Author(s) -

C. H. Chilton,

Jane Freeman,

G. S. Crowther,

S. L. Todhunter,

Scott Nicholson,

M. H. Wilcox

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr584

Subject(s) - clostridium difficile , microbiology and biotechnology , antibiotics , clostridiaceae , clostridium , biology , medicine , bacteria , toxin , genetics

Co-amoxiclav is widely prescribed in hospitals. Although reports have suggested it may be linked to onset of Clostridium difficile infection (CDI), data on the risk of CDI associated with specific antibiotics is difficult to obtain, due to confounding clinical factors. We have examined the propensity of co-amoxiclav to induce CDI using a human gut model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research